24-MONTH RESULTS OF ITRACK GLOBAL DATA REGISTRY TO SUPPORT THE ROLE OF CANALOPLASTY FOR TREATMENT OF GLAUCOMA
Published 2024 - 28th ESCRS Winter Meeting
Reference: FP75 | Type: Submission | DOI: 10.82333/n4q7-xp29
Authors: Karl Mercieca* 1 , Keith Barton 2 , David Lubeck 3
1Universitäts-Augenklinik, Bonn,Bonn,Germany, 2Moorfields Eye Hospital,London,United Kingdom, 3Arbor Centers for EyeCare,Homewood,United States
Purpose
Purpose: The iTrack Global Data Registry (iTGDR) aims to collate efficacy and safety data for canaloplasty including: IOP reduction, number of medications, endothelial cell count, adverse events, and complications, in addition to canaloplasty-specific treatment parameters.
Setting
Prospective multicenter cloud-based database (iTGDR, part of the International Glaucoma Surgery Registry – IGSR)
Methods
Methods: Prospective multicenter in America, Australia, and Europe, cloud-based database, real-world study including patients with primary and secondary open angle glaucoma undergoing canaloplasty. The iTGDR is a surgeon-led initiative conducted in collaboration with the International Glaucoma Surgery Registry (IGSR). It collects longitudinal data of efficacy (IOP, number of medications, RNFL analysis, and HVF), and safety (endothelial cell loss, adverse events, and complications). The iTGDR started in January 2022 in the USA, Canada, Europe, Asia, and Australia. The outcomes will be followed for at least 12 months and a minimum of 300 patients will be enrolled.
Results
Results: 367 eyes have been enrolled up to September 2023. Mean baseline IOP and number of medications were 18.2±5.98 and 2.08±1.19, respectively, and were reduced to 14.4±4.64 and 0.96±1.31, respectively, at 12 months (n=82; p<0.001) and to 11.7±2.98 and 0.74±1.19 at 24 months (n=19; p<0.001 and p=0.004), respectively. Combined phaco-canaloplasty was performed in 88.8% and as a standalone procedure in 11.2% (baseline IOP was 17.9±5.95 and 20.4±5.76 vs 12.2±3.19 and 10.2±1.79 at 24 months postoperatively). 8.2% of the eyes were medication-free at baseline vs 68.4% at 24 months. Hyphema (>10% of the anterior chamber) occurred in 7 eyes (1.91%). No eye required further glaucoma surgery.
Conclusion
Conclusion: The iTGDR will make a major contribution to understanding the clinical effectiveness of canaloplasty to guide evidence-based decision making for surgeons to achieve improved outcomes in the treatment of their glaucoma patients.